Evidence map›Paper›PMID 26521079›Full record

ReviewRheumatology international2016

Focal bone involvement in inflammatory arthritis: the role of IL17.

Maurizio Rossini, Ombretta Viapiana, Silvano Adami, Luca Idolazzi, Elena Fracassi, Davide Gatti

Abstract readReview
PubMed Publisher
In one paragraph

Review in Rheumatology international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Consequences of Aging on Bone.Aging and disease · 2023
    Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Osteoimmunology of Spondyloarthritis.International journal of molecular sciences · 2023
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Journal of personalized medicine · 2021
    Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Maurizio RossiniRheumatology Section, Department of Medicine, University of Verona, Verona, Italy. maurizio.rossini@univr.it.
Ombretta ViapianaRheumatology Section, Department of Medicine, University of Verona, Verona, Italy.
Silvano AdamiRheumatology Section, Department of Medicine, University of Verona, Verona, Italy.
Luca IdolazziRheumatology Section, Department of Medicine, University of Verona, Verona, Italy.
Elena FracassiRheumatology Section, Department of Medicine, University of Verona, Verona, Italy.
Davide GattiRheumatology Section, Department of Medicine, University of Verona, Verona, Italy.
University of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Conditions such as rheumatoid arthritis (RA) and spondyloarthritis (SpA, such as psoriatic arthritis, PsA, and ankylosing spondylitis, AS) are characterized by an imbalance between osteoclast (OC) bone resorption and osteoblast (OB) bone formation. The two conditions present substantial differences in bone involvement, which is probably related to the different expression of IL17 and TNFα, two cytokines that strongly promote osteoclastogenesis and focal bone erosions. TNFα is the major inflammatory cytokine in RA. It acts by both triggering OC bone erosion via the RANK-RANKL system, and suppressing OB bone formation through the overexpression of DKK1, a powerful inhibitor of the WNT bone anabolic signaling pathway. Differing from TNFα, IL17 promotes also osteogenesis, particularly at inflamed sites undergoing mechanical stress, such as entheses. Therefore, in RA, where overexpression of TNFα is higher than IL17, OC bone resorption largely prevails upon bone formation. In PsA and AS, the prevailing inflammatory cytokine is IL17, which promotes also osteogenesis. Given the prevalent involvement of entheses poor of OC, excess bone formation may even prevail over excess bone resorption. The results of clinical trials support the different pathophysiology of bone involvement in chronic arthritis. Inflammation control through anti-TNFα agents has not resulted in incomparable effects on radiographic progression and excess bone formation in both AS and PsA. Clinical trials investigating IL17 inhibitors, such as secukinumab, in patients with psoriatic disease are underway. The preliminary results on inflammation and symptoms appear positive, while long-term studies are required to demonstrate an effect on excess bone formation.

Indexed as

Bone RemodelingAnimalsAnti-Inflammatory AgentsArthritis, RheumatoidBone and BonesHumansInflammation MediatorsInterleukin-17JointsRANK LigandSpondylarthritisWnt Signaling PathwayAnti-Inflammatory AgentsInflammation MediatorsInterleukin-17RANK LigandTNFSF11 protein, humanBone formationBone resorptionIL17RANK–RANKL systemRheumatoid arthritisSpondyloarthritis

Identifiers

PMID26521079
OpenAlexW2098317868

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.